Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Biomarker identification has been a critical component in drug discovery and development. Biomarkers have been utilized in several areas such as disease diagnosis, pharmacokinetics-pharmacodynamics (PK-PD) modeling, evaluation of efficacy and toxicity to guide both pre-clinical compound selection and clinical study of candidate compounds. Recent advances in genomics and bioinformatics have created a new paradigm in the development of robust gene expression signature biomarkers, particularly for predicting toxicity and cancer drug responses. In this article, we present an overview of current progress in this arena including methodology development and applications in the drug discovery process.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: June 1, 2010
More about this publication?
- Current Bioinformatics aims to publish all the latest and outstanding developments in bioinformatics. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a wide range of the integration of biology with computer and information science.
The journal focuses on reviews on advances in computational molecular/structural biology, encompassing areas such as computing in biomedicine and genomics, computational proteomics and systems biology, and metabolic pathway engineering. Developments in these fields have direct implications on key issues related to health care, medicine, genetic disorders, development of agricultural products, renewable energy, environmental protection, etc.
Current Bioinformatics is an essential journal for all academic and industrial researchers who want expert knowledge on all major advances in bioinformatics.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites